Remove Cannabinoids Remove Clinical Trials Remove Conditions Remove Reference
article thumbnail

CBG ‘very helpful’ when treating medical conditions, first survey of its kind finds

The Cannigma

The majority of people who use the cannabinoid cannabigerol (CBG) for medical reasons find it to be helpful or very helpful in treating a variety of health conditions, according to the findings of a recent survey. No clinical trial was used in the compilation of the study. Why is CBG ‘the mother of all cannabinoids?’.

article thumbnail

IGC Completes Cohort 2 of its Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients

Cannabis Law Report

IGC”) (NYSE American: IGC) announces today that it has completed Cohort 2 of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”)-based investigational new drug, IGC-AD1, intended to alleviate the symptoms of individuals suffering from Alzheimer’s disease. This Phase 1 trial is currently testing IGC-AD1 for safety.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Clinical Trial on Alzheimer’s Patients Indicates Positive Safety and Tolerability Data for IGC’s THC-Based Investigational New Drug

Cannabis Law Report

IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease. The trial was conducted as a multiple ascending dose (MAD) study.

article thumbnail

CBN: The Sleep-Inducing Cannabinoid

Kind Meds (Cannabis Education Blog)

CBN is a popular cannabinoid, but what should we know about CBN and sleep? This minor cannabinoid has always existed in the cannabis plant in small quantities, but it is gaining in popularity for its potential healing properties. Unlike some other cannabinoids, it is not present in substantial amounts in fresh cannabis flower.

Sleep 94
article thumbnail

Phase 1 Clinical Trial Data Indicate IGC’s THC-based Investigational New Drug May Reduce Symptoms of Dementia in Alzheimer’s Patients

Cannabis Law Report

(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.

article thumbnail

Unlocking the Potential of CBD: Exploring The Benefits of CBD in Medical Marijuana

MMJ Recs

CBD, one of the many cannabinoids found in the cannabis plant, has been garnering attention for its promising effects on various health conditions. From its anti-inflammatory properties to its ability to alleviate pain, CBD shows promise in addressing various health conditions.

CBD 52
article thumbnail

Understanding the Efficacy of Medical Cannabis for Terminal Care

Canna Care Docs

Alleviating Symptoms with Cannabinoids As more states legalize medical cannabis, many researchers and clinicians are studying the efficacy of cannabinoids like THC and CBD for alleviating these symptoms. One study from the Journal of Clinical Oncology examined the efficacy of cannabinoids in appetite stimulation.